Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial

BACKGROUND AND PURPOSE: Rapid genotyping is useful for guiding early antiplatelet therapy in patients with high-risk nondisabling ischaemic cerebrovascular events (HR-NICE). Conventional genetic testing methods used in CYP2C19 genotype-guided antiplatelet therapy for patients with HR-NICE did not sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xia, Wang, Anxin, Zhang, Guojun, Niu, Siying, Li, Wei, Han, Sifei, Fang, Fang, Zhao, Xingquan, Dong, Kehui, Jin, Zening, Zheng, Huaguang, Chen, Kelin, Li, Hao, Yang, Chengyuan, Wang, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258065/
https://www.ncbi.nlm.nih.gov/pubmed/33952669
http://dx.doi.org/10.1136/svn-2021-000874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258065/
https://www.ncbi.nlm.nih.gov/pubmed/33952669
http://dx.doi.org/10.1136/svn-2021-000874

Ejemplares similares